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Abstract
Background: Uveitis is a potentially blinding inflammatory disease of the inner eye with a high unmet need for
new therapeutic interventions. Here, we wanted to investigate the suppressive effect of the intraocular application
of the small molecule dihydroorotate dehydrogenase (DHODH)-inhibitor PP-001 on experimental relapsing rat
uveitis and furthermore determine its effect on proliferation and cytokine secretion of human peripheral blood
lymphocytes (PBL) and human retinal pigment epithelial (RPE) cells in vitro.
Methods: Spontaneously relapsing uveitis was induced in rats by immunization with interphotoreceptor retinoid-
binding protein (IRBP) peptide R14. PP-001 was injected intravitreally after resolution of the primary disease to
investigate further relapses. Proliferation and metabolic activity of phytohemagglutinin (PHA)-stimulated human
peripheral lymphocytes with and without PP-001 and cytokine secretion were determined by XTT assay and
bioplex bead assay. The RPE cell line ARPE-19 as well as primary human RPE cells treated with PP-001 or anti-
vascular endothelial growth factor (VEGF) antibody bevacizumab were also investigated for metabolic activity
and cytokine/chemokine secretion.
Results: Injection of PP-001 into rat eyes reduced the number of relapses by 70%, from 20 relapses (57% of the rats
affected) in the control group to 6 relapses (33% of the rats) in the treatment group. In human PBL cultures, PP-001
reduced the proliferation in a dose-dependent manner. The secretion of several cytokines such as IL-17, IFN-γ, and
VEGF was suppressed by PP-001, as previously observed with rat T cells in the experimental autoimmune uveitis
(EAU) model. In contrast, human RPE cells were not affected by PP-001, while the anti-VEGF antibody bevacizumab
severely impaired the secretion of various cytokines including VEGF.
Conclusions: For the first time, intravitreal injection of PP-001 demonstrated an effective, but transient reduction of
relapses in the rat EAU model. In vitro PP-001 suppressed proliferation and cytokine/chemokine secretion of human
lymphocytes, while neither human RPE cell line ARPE-19 nor primary RPE cells were affected.
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Background
Uveitis is a potentially blinding inflammatory disease of
the inner eye. Autoimmune uveitis requires systemic
immunosuppressive therapy of patients, which is fre-
quently burdened with severe side effects. The choice of
therapeutics for uveitis is modest, with corticosteroids,
cyclosporine, and TNF-blocking agents as well as off-label
use of methotrexate, azathioprine, and mycophenolates
[1]; there is an urgent need for new and potent drugs
causing less side effects. We have recently described the
effect of oral administration of PP-001 (biphenyl-4-yl-car-
bamoylthiophene-2-carboxylic acid derivative), a new in-
hibitor of dihydroorotate dehydrogenase (DHODH), in
two different experimental autoimmune uveitis (EAU)
models in Lewis rats on inflammation as well as secondary
neovascularization [2].
The two rat models of EAU are characterized by either
a monophasic course of inflammation with neovasculari-
zations as late sequel after immunization with S-Ag pep-
tide PDSAg or a spontaneously relapsing-remitting
course after immunization with IRBP peptide R14. In
addition, we have shown the downregulation of prolifer-
ation and cytokine/chemokine secretion by autoreactive
rat T cell lines. T cells specific for PDSAg secrete vascu-
lar endothelial growth factor (VEGF), and only PDSAg-
induced EAU shows chorioretinal neovascularizations
(CNV), despite a usually severe destruction of the retina
in both types of uveitis and the fact that we observe
CNV even in eyes with minor affection of the retina. We
thus concluded that neovascularization in uveitis eyes is
induced by the VEGF secretion of the intraocular T cells,
since blocking T cells and their VEGF secretion by PP-
001 prevented CNV in this type of EAU [2].
DHODH is an enzyme necessary for pyrimidine
synthesis. PP-001 inhibits DHODH with a 150-fold
higher potency than teriflunomide and especially targets
activating T cells with an enhanced requirement for py-
rimidines, which can only be covered by de novo synthe-
sis [3]. Since systemic inhibition of T cell activation leads
to a generalized immunosuppression, we are aiming at
an intraocular application of PP-001 to only affect the
local autoimmune response while sparing systemic
immunity. Here, we show the effect of intravitreally
injected PP-001 solution on the course of relapsing rat
EAU. Moreover, we have investigated the in vitro effect
of the small molecule on human peripheral lymphocytes
and different retinal pigment epithelial (RPE) cells
regarding proliferation and metabolic activity as well as
cytokine and chemokine production. Since VEGF-
production in PDSAg-specific, autoreactive rat T cells
and chorioretinal neovascularizations in EAU can be
suppressed by PP-001, we were interested whether PP-
001 could also inhibit VEGF-secretion in human RPE
cells [2]. For this purpose, we have compared the effect
of PP-001 and the therapeutic VEGF inhibitor bevacizu-
mab (Avastin®) on the human RPE cell line ARPE-19
and on primary human RPE cells, investigating cytokine
and growth factor secretion. We looked at proliferation
and metabolic activity and cytokine/chemokine secretion
to compare it with the effect on activated human periph-
eral blood lymphocytes in vitro. While PP-001 efficiently
downregulated proliferation and the secretion of a range
of cytokines and chemokines in activated human periph-
eral blood lymphocytes, ARPE-19 cells and primary RPE
cells were not affected. In contrast, the therapeutic
VEGF inhibitor bevacizumab (Avastin®) dramatically
suppressed the secretion of several cytokines by human
RPE cells, including VEGF. Our data suggest that in uve-
itis patients PP-001 would specifically target intraocular
T cells and their VEGF secretion and subsequent CNV
induction, but without disturbing the homeostasis of
basal VEGF-secretion of RPE cells that maintains the in-
tegrity of the choriocapillaris.
Methods
Induction of EAU in rats
Male and female Lewis rats (Lew/Orl Rj) were bred
in our own colony or purchased from Janvier
(Le-Genest-St-Isle, France). They were maintained
under specific pathogen-free conditions with water
and food ad libitum and used for experiments at the
age of 6–8 weeks. Animals were immunized subcuta-
neously into both hind legs (50 μl/side) with a total
volume of 100 μl emulsion containing 15 μg peptide
R14 (human IRBP aa 1169-1191; Polypeptide Labora-
tories, France) and complete Freund’s adjuvant
(CFA), fortified with mycobacterium tuberculosis
strain H37RA (BD Biosciences, Germany) to a final
concentration of 2.5 mg/ml. The time course of uve-
itis was determined by daily examination of animals
with an ophthalmoscope and graded as described [4].
Clinical grading of the anterior chamber in brief, 0.5:
enlargement of iris vessels, 1: peripupillar infiltration
of leukocytes, 2: pupil covered with a fibrin clot, 3:
anterior chamber hypopyon, and 4: anterior chamber
hemorrhage. A relapse of EAU was defined as a
score of > 0.5 after the resolution of the first course
of inflammation and/or a period with a score of
≤0.5 or complete absence of all clinical signs of
inflammation.
Intraocular injection of rat eyes
Lewis rats (n = 30; age 6–8 weeks) were anesthetized
using 0.5 mg/kg medetomidine s.c. Additional topical
anesthesia with 0.4% oxybuprocaine eye drops was ap-
plied. After intraocular injection, sedation was antago-
nized with an s.c. injection of 2.5 mg/kg atipamezol. A
stock solution of 35.5 mM PP-001 (MW 479.33;
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Panoptes Pharma GmbH, Austria, corresponding to
17 mg/ml) in absolute ethanol was diluted with sterile
0.9% saline to the final concentration of 0.5 or
0.8 μg/μl. Six microliters of solution with or without
PP-001 (6.3/10.4 μM as indicated) were injected into
the vitreous of both eyes with a 30G needle,
controlled under an operation microscope. The per-
pendicular injection is penetrating the cornea without
touching the lens or the retina. After injection, an
antibiotic ointment was applied to the eyes to avoid
infections.
Intravitreal injection of rabbit eyes and measurement of
intraocular PP-001 levels
Male Dutch belted rabbits of 13 to 18 weeks from
Western Oregon Rabbit Company were used, and the
experiments performed by Absorption Systems Inc.
(ASI, San Diego, USA). They were housed in individ-
ual cages with water and food ad libitum. Procedures
involving the care or use of animals in this study
were reviewed and approved by the company’s Insti-
tutional Animal Care and Use Committee (IACUC).
Animals were anesthetized with an i.m. injection of
ketamine hydrochloride (30 mg/kg) and xylazine
(5 mg/kg) for the injection procedure. Topical ocular
anesthetics were used. The eyes and surrounding tis-
sues were disinfected with 2% betadine ophthalmic
solution and then rinsed with saline. Using a 30G
needle, 25 μl PP-001 per eye was injected transscler-
ally 5 to 7 mm from the limbus. Both eyes were enu-
cleated from animals euthanized by an intravenous
injection of a commercial barbiturate-based euthan-
asia solution (150 mg/kg). The procedure was per-
formed in compliance with the 2013 American
Veterinary Medical Association (AVMA) Guidelines
on Euthanasia. The eyes were rinsed with phosphate-
buffered saline, and the retina was immediately dis-
sected from each eye, snap frozen, and stored at −
70 °C until analysis. After thawing and addition of
PBS and DMSO (1:1), the samples were homogenized
and sonicated. Retina samples were homogenized
using a MagnaLyser (Roche). The analysis of samples
is based on determination of the analytes using tan-
dem mass spectrometry after high-performance liquid
chromatography. Pharmacokinetic parameters were
calculated from the time course of the tissue concen-
trations. Pharmacokinetic parameters were determined
with Phoenix WinNonlin (v6.3) software using a non-
compartmental model with sparse sampling.
Human peripheral blood lymphocytes
Collection of peripheral blood lymphocytes (PBL) from
anonymized human donors with informed consent was
approved by the ethics committee of the University
Hospital, LMU Munich. Lymphocytes from heparinized
blood of four healthy male donors (aged 26–35) were
separated by a ficoll gradient and set up as triplicate cul-
tures in RPMI1640 without phenol red supplemented
with 4 mM L-glutamine, 1 mM sodium pyruvate, MEM
non-essential amino acids, and 50 U penicillin/50 mg
streptomycin (all from SIGMA, Deisenhofen, Germany)
with or without 1% phytohemagglutinin (PHA) (Difco
BD, Heidelberg, Germany) at a density of 1 × 106/ml
(cytokine detection in supernatants) or 2 × 106/ml (XTT
assays). Heat-inactivated human serum pool was added
to a concentration of 5%. PP-001 was added to the
cultures in concentrations of 3 μM (1.44 μg), 10 μM
(4.8 μg), and 30 μM (14.4 μg) for XTT assay and 3 and
30 μM for the cytokine/chemokine detection for 72 h.
Parallel assays were set up for XTT assay and collection
of supernatants. Controls included cultures without test
substance but with the diluent of PP-001.
Retinal pigment epithelial cell line
The immortalized retinal pigment epithelial cell line
ARPE-19 (ATTC® CRL-2302™) was cultured in DMEM/
Ham’s F12 medium with stable glutamine supplemented
with 50 U penicillin/50 mg streptomycin and 10%/FCS
(Biochrom, Berlin, Germany). Confluent cells from
passage 24 were transferred to 96-well microplates and
cultured for 4 days as confluent cell layer before the
medium was exchanged and PP-001 or anti-VEGF
antibody bevacizumab (Roche Pharma AG, Grenzach-
Wyhlen, Germany) were added to triplicate cultures.
Controls without test substance but with the diluent of
PP-001 were included. Culture supernatants were
collected as described for human PBL and tested for
cytokine/chemokine.
Primary retinal pigment epithelial cells
The isolation of RPE cells (RPE 80.1 and RPE 81.6) from
human cadaver eyes (anonymized donors) for scientific
purposes was approved by the ethics committee of the
Land Oberoesterreich. Human postmortem donor eyes
were obtained from the Eye Bank of the Department of
Ophthalmology at the Linz General Hospital (Linz,
Austria) and processed within 4–24 h after death to ob-
tain RPE cells. Isolation of human RPE cells was per-
formed as described previously [5]. Human RPE cells of
passage 4 from two different donors were used for the
experiments. Cells were maintained in DMEM/Ham’s
F12 (Biochrom) supplemented with 10% FCS. For stimu-
lation experiments, the cells were confluently seeded on
96-well plates (passage 4) 4 days before adding PP-001
or bevacizumab to triplicate cultures for 72 h. Controls
included cultures without test substance but with the
diluent of PP-001. Supernatants were collected and
tested for cytokines as described above.
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XTT-assays
XTTassays to determine proliferation and metabolic activ-
ity of human PBL after 72 h of culture were performed ac-
cording to the manufacturer’s instruction (R&D Systems,
Wiesbaden, Germany). Optical density (OD) was mea-
sured at 490 nm after 5 h of assay time.
Bioplex bead assays to detect cytokines/chemokines
To determine cytokine secretion and to detect early and
late secreted cytokines, 25 μl of supernatant was col-
lected daily (24, 48, and 72 h) from each well of each
triplicate, pooled, and immediately frozen at − 80 °C. Su-
pernatants of triplicates from all time points (9 samples)
were pooled immediately before testing with a Bioplex
Pro Human Cytokine and Chemokine Assay (BioRad,
Munich, Germany) for 29 analytes with a flow
cytometry-based Luminex reader. Fifty microliters of
supernatants were used for the assay according to the
manufacturer’s instruction and tested for IL-1β, IL-
1RA, IL-2, IL-4, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10,
IL12p70, IL-13, IL-15, IL-17A, Eotaxin/CCL11, basic
FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1/CCL2,
MIP-1α/CCL3, MIP-1β/CCL4, PDGF, RANTES/CCL5,
TNF-α, VEGF, MCP-3/CCL7, MIP-3α/CCL20, and
SDF-1α+β/CXCL12. The final values obtained in the
bioplex analysis are calculated from the median value
of fluorescence of at least 50 measured beads per
analyte and sample.
Statistics
Statistics was performed with InStat software using
nonparametric (Mann-Whitney) tests (Table 1). For mul-
tiple comparison, Kruskal-Wallis test (nonparametric
ANOVA) was used. P values ≤ 0.05 were regarded as
significant.
Results
Intraocular injection of PP-001
Clinical course of R14-induced relapsing EAU in rats after
intravitreal injection of PP-001
PP-001 or PBS was injected intravitreally in two inde-
pendent experiments with a final group size of 15 rats
that had R14-induced relapsing EAU. The injection was
performed when the primary clinical disease course had
resolved to a score of ≦ 0.5 (day 18 post immunization),
and disease progression was observed and graded until
day 31 (Fig. 1). The clinical grading only considers signs
of inflammation in the anterior part of the eye, since
haze (score 1) and fibrin clotting the pupil (score 2)
prevent investigation of the posterior segment. One eye
of the PP-001-treated group (Fig. 1, no. 7) was perfo-
rated during the injection procedure and thus excluded
from the study. Two independent experiments were per-
formed with similar results; representative time courses
from the first experiment are shown in Fig. 1, and the
combined data from both experiments are given in
Table 1. In the first experiment 3 μg PP-001 (6.3 μM)
was injected into each eye of the treatment group (n =
10 rats, 20 eyes, Fig. 1). In the second experiment 5 μg
PP-001 (10.4 μM) was used (5 rats, 10 eyes, time courses
not shown). The rats of both treatment groups had a
similar disease course prior to injection with maximal
uveitis scores of 2.6 and 2.7, respectively, and a similar
response to the treatment. In the PP-001-injected group,
29 eyes experienced 6 relapses, whereas in the vehicle-
injected group, 20 relapses occurred in 30 eyes. Two
eyes of the vehicle-injected group had 2 relapses, so 18
of 30 eyes in the control group were affected during the
first 6 days post injection (days 19 to 24, Table 1). The
reduction of relapses in the PP-001-treated group in re-
lation to the control group was significant and substan-
tial. In the control group, 73% (11/15 rats) of the
Table 1 Effect of intravitreal injection of PP-001 on R14-induced relapsing EAU in rats
Vehicle PP-001
Mean max. clin. uveitis score primary disease (score 0 – 4 ± SE) 2.6 ± 0.1 2.7 ± 0.1
Mean max. clin. uveitis score at
day of injection (score 0 – 4 ± SE)
0.5 ± 0.1 0.4 ± 0.1
Total no. of relapses post injection until day 6 20 6
No. of eyes with multiple relapses 2 0
No. of eyes with relapses 18 out of 30 eyes (60%)* 6 out of 29 eyes (21%)*
Relapses/animals 11/15 (73%)* 5/15 (33%)*
Mean max. uveitis score/relapse (score 0 – 4 ± SE) 1.1 ± 0.1 1.2 ± 0.3
Mean duration of relapse (days ± SE) 1.45 ± 0.11 1.17 ± 0.17
Mean appearance of first relapse (days post injection ± SE) 3.4 ± 0.5 4.3 ± 0.9
Mean severity of uveitis post injection until day 6 (± SE) 2.22 ± 0.25* 1.34 ± 0.22*
“Mean severity of uveitis” is the mean of daily uveitis scores calculated over a certain period of time. One eye of the PP-001-treated group (rat 7/PP-001,
see Fig. 1) was perforated during injection and not considered. Data are pooled from two independent experiments, Exp. 1, n = 10; Exp. 2, n = 5
rats/group. *p < 0.05
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animals had relapses, but only 33% (5/15 rats) in the PP-
001-treated group. The number of eyes and the number
of animals with relapses were significantly reduced in
the PP-001-treated compared to the vehicle-treated
group (p < 0.05), also the average daily intensity of in-
flammation from days 19 to 24 (p < 0.05) (PP-001, 1.34
± 0.22; vehicle, 2.22 ± 0.25). The mean number of re-
lapses/rat was 0.733 (CI 0.480–0.987) in the PBS-treated
group and 0.33 (CI 0.063–0.604) in the PP-001-treated
group; the mean number of relapses/eye was 0.633 (CI
0.365–0.902) in the control group and 0.241 (CI 0.076–
0.407) in the PP-001 group. The average daily intensity
of inflammation is shown as “severity of uveitis over
time” and was calculated by the summation of the daily
uveitis scores of all eyes in one group divided by the
number of eyes and number of days (Table 1). PP-001
showed a significant transient suppressive effect on the
relapses in R14-induced relapsing EAU. The duration of
the effect is supported by a pharmacokinetic analysis of
the retina after intravitreal injection (Fig. 2). It even sug-
gests that a single local supply of efficacious dose levels
of PP-001 for 24 to 48 h is sufficient to show an effect
on relapses of EAU for 6 days.
Pharmacokinetic of PP-001 in rabbit eyes
To further investigate the fate of PP-001 within the eye,
pharmacokinetic studies of PP-001 in different ocular
tissues were performed after intravitreal injection of
62.5 μg PP-001 into the eyes of Dutch belted rabbits.
During the first 4 h post injection, the retinal concentra-
tion of PP-001 was stable between 83 and 98 μg/g retina
and dropped thereafter (Fig. 2). A terminal half-life (t1/2)
of 13.6 h was determined. After 48 h, the PP-001 con-
centration in the retina was still 3 μM, a concentration
that was still highly suppressive for human lymphocytes,
as shown in Figs. 3 and 4. PP-001 levels were compar-
able in choroid and in vitreous humor at all time points
and AUC (area under the curve; which is integral in a
plot of drug concentration in blood plasma vs. time) was
1/3 of that of the retina. After intravitreal injection of
62.5 μg PP-001, plasma concentrations were very low
(Cmax = 41 ng/ml). Plasma levels were > 2000-fold
lower than respective retina levels (maximal level
40.9 ng PP-001/ml), and potential systemic anti-
inflammatory activity of PP-001 can be neglected at
such low plasma concentrations. We have refrained
from testing PP-001 levels in the inflamed eyes, since
it has been published that there are no major
1
2
3
4
5
6
7
8
9
10
Fig. 1 1–10 Clinical course of R14-induced relapsing EAU in rats after
intravitreal injection of PP-001. Both rat eyes were injected once
intravitreally with 6 μl PBS or 3 μg PP-001/6 μl PBS at day 18 (dashed
line, resolution of primary inflammation) post immunization with R14-
CFA. The clinical course is shown for each eye from each rat of both
groups. The dotted line at day 24 defines the time period of thera-
peutic activity of intraocular PP-001. Relapses were defined as a clinical
score of > 0.5 following a score ≦ 0.5. * Indicate relapses between days
19 and 24, + the relapses from day 25 until the end of the experiment.
The gray areas show the negative/low inflammation scores that have to
be exceeded for the definition of a relapse. Triangles: right eyes, black
dots: left eyes. The right eye of rat PP-001/no. 7 was perforated during
the injection and thus omitted from further evaluation. N= 10 rats per
group; PBS n = 20 eyes, PP-001 n = 19 eyes after injection.
Representative data are shown from experiment 1 of two
independent experiments
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differences expected in the pharmacokinetics between
healthy and diseased eyes [6].
Effect of PP-001 on human lymphocytes and retinal pigment
epithelial cells
We have previously shown that PP-001 efficiently re-
duced proliferation and metabolism as well as cytokine
secretion of rat T cells in vitro, and one of the key cyto-
kines affected by PP-001 was VEGF in PDSAg-specific T
cells [2]. Thus, we investigated whether PP-001 would
have similar effects on human lymphocytes and on ret-
inal pigment epithelial cells.
XTT assay to determine metabolic activity
Metabolic activity and proliferation of human PHA-
stimulated PBL were significantly suppressed in a dose-
dependent manner by PP-001 as determined by XTT assay
(Fig. 3a), while no effect was observed on human RPE cells
ARPE-19 (Fig. 3b). Figure 3a shows the mean percentage
of inhibition of PHA-stimulated PBL from four donors
(the same as those assayed for cytokine secretion in Fig. 4)
with increasing concentrations of PP-001.
Cytokine secretion
Cytokine secretion was measured in culture superna-
tants from PBL stimulated with PHA and treated with
PP-001 in doses of 3 and 30 μM. Only data from those
cytokines and chemokines with a level above the detec-
tion threshold of the assay from the four donors are
shown in Fig. 4. Since the tested donor lymphocytes
showed similar pattern in response to PP-001, but highly
varied in the amounts of secreted factors, we have calcu-
lated the mean percentage of alteration of cytokine se-
cretion compared to PHA stimulation only, the latter
was defined as 100%. The highest amounts of secreted
cytokines from PHA-stimulated PBL were determined
for IFN-γ and TNF-α, followed by IL-6, IL-13, IL-2, and
GM-CSF. The secretion of IL-8 from PBL is not shown,
since it exceeded the detection level of the assay in all
PHA-stimulated cultures. IL-17 secretion was moderate
and even lower than IL-10, MIP-1a/CCL3, and VEGF.
The lowest concentration of PP-001 (3 μM) already
efficiently and significantly suppressed the secretion of
the T cell-produced cytokines IL-2, IFN-γ, IL-17, IL-13,
IL-10, TNF-α, VEGF, and GM-CSF, while the secretion
of mainly monocyte-produced interleukins (monokines)
IL-1β, IL-1ra, MCP-1/CCL2, MCP-3/CCL7, MIP-1β/
a
b
Fig. 3 Proliferation and survival (metabolic activity) of PHA-stimulated
human PBL and ARPE-19 cells treated with PP-001. a Inhibition of
PHA-stimulated human peripheral blood cells from four different
donors with PP-001, determined by XTT assay. OD 490 was measured
after 72 h of PBL culture in triplicates with medium only, PHA and PHA
with different concentrations of PP-001. Mean medium control values
were subtracted from the mean values of stimulated cultures of each
individual donor. Data of cultures stimulated with PHA only were de-
fined as 100%; the percentage of activity (OD 490) is calculated in
relation to the PHA control for each donor. Data show the means of %
OD490 + SE from all donors. b XTT assay of triplicate cultures of ARPE-
19 cells being confluent for 4 days and treated with either PP-001 or
medium only. OD 490 was determined after 72 h of culture. Data are
shown as mean OD 490 + SD
Fig. 2 Pharmacokinetic profiles of PP-001 in rabbit eyes. Retinal
concentration of PP-001 after intravitreal injection of 62.5 μg PP-001/
rabbit eye (0 h). Tissues were collected at the indicated time points;
PP-001 concentration is shown as nanogram per milligram/retina. N= 2
rabbits/4 eyes for each time point. Mean concentrations of PP-001 ± SD
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CCL4, and MIP-3α/CCL20 was not suppressed by PP-
001, suggesting that the T cell response, but not the in-
nate immune response, was inhibited by treatment with
PP-001. IL-6 and MIP-1α/CCL3 are produced by both T
cells and myeloid cells and were not (MIP-1α/CCL3) or
only slightly inhibited with 30 μM PP-001 (IL-6), sug-
gesting that innate cells might have compensated for the
suppressed T cell secretion of these factors (Fig. 4).
Human RPE cells were also co-cultured with various
doses of PP-001 and bevacizumab as indicated (Fig. 5),
and culture supernatant was collected daily to determine
secreted cytokines, chemokines, and growth factors. As
described for the human PBL above, only those cyto-
kines/chemokines produced in amounts within the
detection levels of the bioplex assay are shown in Fig. 5.
ARPE-19 cells and the primary human RPE cells se-
creted a number of cytokines, chemokines, and VEGF as
the predominant growth factor. ARPE-19 cells had a
higher baseline secretion of all factors compared to pri-
mary RPE cells from passage 4, except for IL-6, which
was secreted in higher amounts by the primary RPE 80.1
cells (Fig. 5).
While PP-001 had almost no effect on the secretion of
the tested factors and only slightly reduced the secretion
of VEGF from ARPE-19 cells, bevacizumab efficiently
suppressed IFN-γ, IL-10, IL-12, and IL-13 as well as
VEGF secretion of ARPE-19 cells and the primary hu-
man RPE cells 80.1. IFN-γ, expressed at low levels in pri-
mary RPE, was only slightly diminished by bevacizumab,
while the rather low IL-13 secretion was suppressed in
RPE 80.1, but not RPE 81.6.
IL-8 production was enhanced in a dose-dependent
manner with both, PP-001 and bevacizumab in ARPE-
19, but not in primary RPE cells. IL-6, MCP-1/CCL2,
and IP-10/CXCL10 secretion was not affected in any of
the cells with both PP-001 and bevacizumab.
Despite the strong suppressive effect of PP-001 on
lymphocytes, RPE cells remained unaffected. In contrast,
bevacizumab, which is used for intraocular injections in
case of uveitis neovascularizations, suppressed cytokine
secretion of RPE cells. Bevacizumab thus might influ-
ence the function and role of RPE cells in the ocular
immune privilege and their interaction with neighboring
ocular structures like the choriocapillaris and choroid.
Fig. 4 Cytokine secretion of PHA-stimulated human PBL treated with
PP-001. Cytokine secretion of PHA-stimulated human PBL from four donors
with or without PP-001 (3 and 30 μM, respectively). Supernatants from
triplicate cultures were collected at three time points (24, 48, and 72 h
after onset of cultures, in total nine samples) and pooled for the final
bioplex analysis. Cytokine secretion of cultures with PHA only is defined
as 100%; the percentage of secretion in cultures with PP-001 is respectively
calculated in relation to the PHA-control for each donor. Data show the
means of % secretion from four different donors + SE, p values are only
shown for significantly different data
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Fig. 5 Cytokine/chemokine of human RPE cells treated with PP-001 or bevacizumab. Secretion of various factors by ARPE-19 cell line or two different primary
human RPE cells (RPE 80.1 and RPE 81.6) cultured with different concentrations of PP-001 (black columns) or bevacizumab (μg/well). Supernatants from
triplicate cultures collected at three time points (24, 48, and 72 h after onset of cultures, in total nine samples) were pooled for the final bioplex analysis.
Data show the mean fluorescence of > 50 measured beads/analyte. “Control” (white columns) are the supernatants from cells cultured without inhibitor.
Dashed lines indicate the baseline secretion of the cells according to the control culture
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Discussion
Autoimmune uveitis is usually treated with systemic im-
munosuppressive agents, especially when the posterior
part of the eye is affected. To avoid side effects of gen-
eral immunosuppression, local treatment by intraocular
injection of anti-inflammatory or immunosuppressive
drugs is desirable. Since we have shown previously that
daily oral application of the small molecule DHODH-
inhibitor PP-001 is highly effective in suppressing
experimental autoimmune uveitis in two different rat
models (relapsing-remitting and chronic disease with
neovascularizations) [2], we decided to investigate its
therapeutic effect after intraocular injection. We have
chosen our relapsing-remitting model to prevent re-
lapses with a single intravitreal application of PP-001
after the primary uveitis attack had resolved, and we
could observe a strongly reduced relapse rate with
significantly less intense inflammation in the PP-001-
injected eyes within 6 days after treatment. This is the
first time that the DHODH-inhibitor PP-001 was proven
to be active not only systemically, but also after local, in-
travitreal injection.
The short-term effect was thought to be due to the
limited retention time of the therapeutic substance in
ocular tissues after intraocular injection, which was
subsequently confirmed by pharmacokinetic studies of
PP-001 in rabbit eyes. The duration of the therapeutic ef-
fect exceeded the actual presence of PP-001 most likely
due to the suppression of local autoreactive T cells, which
remain in the eyes even after the resolution of ocular in-
flammation and can initiate recurrences of inflammation
[7, 8]. Tissue-resident T cells, which are reactivated later,
or newly immigrating T cells would not be affected any
more. This could explain the decreased effect on relapses
of EAU later than 6 days post injection of PP-001.
After the first attack of uveitis had resolved to an ac-
tivity score of 0.5 or less, some eyes showed increased
inflammation at the time of injection of PP-001 in both
groups. From the clinical point of view, this would be a
typical scenario for the treatment in humans. Despite
the increased activity, PP-001 still had a therapeutic ef-
fect. Overall, a single injection of aqueous formulated
PP-001 was sufficient to achieve a local effect in the tar-
get tissue for several days. For long-lasting effects, the
development of sustained release formulations is needed.
In rat models, PP-001 was shown to suppress in vitro
proliferation of autoreactive T cells as well as secretion
of certain inflammatory cytokines and chemokines [2].
Here, we demonstrate the suppression of proliferation of
PHA-stimulated human PBL by increasing doses of PP-
001, yet not below the level of the (unstimulated)
medium control, which indicates that PP-001 was not
cytotoxic. Cytotoxicity for PBL was also excluded by
daily determination of the viability of cells, which was
not diminished even at high concentrations (30 μM) of
PP-001 (data not shown). The secretion of cytokines and
chemokines of peripheral lymphocytes and RPE cells re-
vealed that the levels of some factors secreted by PBL
are strongly decreased with increasing doses of PP-001,
while others remained unchanged or even increased.
The latter is also arguing against general cytotoxicity of
the small molecule. As observed with rat T cells [2],
IFN-γ, IL-17, TNF-α, and VEGF secretion was also
strongly suppressed by PP-001 in human PBL. Since
these cytokines play pivotal roles in inflammation in
uveitis the inhibition of intraocular T cells by an immu-
nomodulating agent like PP-001 would be of high thera-
peutic relevance [8–10].
Also, IL-2, IL-10, GM-CSF, and even the Th2 cytokine
IL-13 were strongly downregulated. It is concluded from
our data that the DHODH-inhibitor PP-001 has more
influence on the cytokine secretion of lymphocytes than
on monocytes/macrophages. The reason is most likely
found in the higher demand for de novo pyrimidine syn-
thesis during the activation of lymphocytes, conveying
the specificity of PP-001 for T and B cells [3].
VEGF can be secreted by activated T cells and induce
Th1 responses [11, 12], and we have previously shown
that only rats with PDSAg-induced EAU developed
chorioretinal neovascularization (CNV). Retinal destruc-
tion is usually severe in both types of EAU (monophasic
and relapsing), and we observe CNV even in those eyes
with only minor destruction of the retina [2], so we
hypothesize that CNV in uveitis is induced by the
VEGF-secretion of the intraocular PDSAg-specific T
cells rather than by ocular cells like RPE. This is sup-
ported by the fact that suppressing the T cells (and their
VEGF secretion) by PP-001 was sufficient to prevent
neovascularization in PDSAg-induced EAU [2].
The inhibition of VEGF secretion of human lympho-
cytes, but not of RPE cells by PP-001 might also be of
therapeutic value for intraocular treatment in human
uveitis cases with this sequel [13, 14]. In patients, neo-
vascularization has been described in cases of choroiditis
or chorioretinitis, where treatment with VEGF-inhibitors
is very successful [15]. It is assumed that, similar to the
generation of lesions in AMD, local VEGF-production
induces CNV. In addition, retinal neovascularization
may develop in retinal inflammation like vasculitis with-
out angiographic signs of ischemia or alterations of the
RPE or choroid [13]. It may be speculated that in these
patients, increased VEGF levels originate from inflam-
matory T cells located in the vitreous, retina, or the
perivascular space and induce sprouting of new vessels
out of the retinal vasculature. This would be consistent
with the neovascularization observed in rat EAU.
Since VEGF is a therapeutic target for wet age-related
macular degeneration (AMD) in patients, we were
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interested whether PP-001 could also suppress VEGF se-
cretion by human retinal pigment epithelial cells, which
are the major source of VEGF in AMD.
The anti-VEGF antibody bevacizumab had a marked
effect on the secretion of several cytokines and especially
on VEGF-secretion of RPE cells, while PP-001 had only
marginal effects. We speculate that the decreased secre-
tion of many cytokines by RPE cells could result from
the depletion of VEGF, an important autocrine survival
factor of RPE cells, by the VEGF-neutralizing antibody
[16]. In contrast, secretion of IL-8/CXCL8 was increased
by both PP-001 and bevacizumab. Like VEGF, IL-8/
CXCL8 also is an angiogenic [17] and anti-apoptotic sur-
vival factor for RPE cells [18], and both cytokines can in-
duce neovascularization. VEGF even has the function of
an autocrine survival factor for RPE cells [19, 20], and it
is furthermore needed to maintain the vessels of the
choriocapillaris [16, 21].
ARPE-19 cells express both VEGF receptors, VEGFR1
and VEGFR2, the latter is the major receptor to induce
angiogenesis and to promote survival of RPE cells [22].
However, despite the positive effect of VEGF block-
ade on the leakiness of vessels and regression of neo-
vascularization, severe damage like geographic atrophy
and poor vision has been observed in AMD patients
after extended treatment with anti-VEGF antibodies
[23–25]. These adverse side effects would not be ex-
pected after PP-001 treatment, which is not affecting
the RPE cells. Our data suggest that in patients with
retinal vasculitis, PP-001 would specifically target
intraocular T cells and their VEGF secretion and sub-
sequent induction of neovascularization without dis-
turbing the homeostasis of basal VEGF-secretion of
RPE cells that is necessary to maintain the integrity of
the choriocapillaris [21].
Regarding the effects of PP-001 on lymphocytes, our
data suggest that the suppression of cytokine secretion
is not a mere effect of suppression of proliferation and/
or the metabolism of the T cells by impeding pyrimidine
synthesis, but there must be additional mechanisms,
probably due to posttranscriptional regulation, as de-
scribed for cytokines and chemokines by Fan et al. [26].
Increased mRNA stability might explain the increase of
IL-8 secretion under PP-001 treatment in ARPE-19
cells.
During treatment with PP-001 and bevacizumab, IL-8
might serve as an autocrine survival factor for RPE, as
described for endothelial cells [18, 27]. Moreover, inter-
action of IL-8/CXCL8 with its receptor CXCR2, both
expressed by RPE cells, upregulates VEGF mRNA and
protein, which results in autocrine activation of VEGFR2
[28, 29]. Increased IL-8 production might therefore be a
compensatory mechanism when VEGF secretion is
inhibited.
Conclusions
The small molecule DHODH-inhibitor PP-001 is a use-
ful therapeutic agent for intraocular application in auto-
immune uveitis. PP-001 could suppress lymphocytes
without affecting ocular tissues like the retinal pigment
epithelium. In the latter case, the integrity of the chorio-
capillaris and the choroid will be preserved, in contrast
to the current treatment of intraocular neovasculariza-
tion with VEGF blockers. Sustained release formulations
for intravitreal application of PP-001 are currently devel-
oped to prolong the efficacy of the treatment to several
months post injection.
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